



caprotec bioanalytics GmbH Appoints Dr. Mathias Grote as Chief Financial and Chief Operating Officer

Berlin, Germany, March 13, 2008 – caprotec bioanalytics GmbH announced today the appointment of Dr. Mathias Grote as Chief Financial Officer and Chief Operating Officer of the Company. Before joining caprotec bioanalytics, Dr. Grote held various senior management positions within the pharmaceutical and biotech industry, most recently as CEO of Pelias AG. Positions held prior to that included Senior Vice President of Commercial Operations at Intercell AG, Chief Business Officer of Noxxon AG, and 15 years at Chiron Vaccines (formerly Behring).

"We are delighted to have Dr. Grote join our management team," said Caprotec founder and CEO Prof. Dr. Hubert Köster. "His outstanding senior-level track record within the biopharmaceutical industry, specifically with product commercialization and creating key pharmaceutical partnerships, will be of particular importance as the Company prepares to commercialize its proprietary CCMS technology and its exciting IMPROMED application to investigate the mechanism of drug action and to identify and reduce side effects of small molecules."

"caprotec's exciting CCMS technology closes an existing gap in the field of proteomics research and has the potential of becoming a tool for proteins as PCR is for DNA," stated Dr. Grote. "The technology has already been validated by proof-of-principle experiments, and I look forward to contributing to the successful commercialization of this technology in its broad range of applications."

About caprotec bioanalytics GmbH

caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry™ (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.

caprotec bioanalytics was founded in 2006 by Prof. Dr. Hubert Köster, an acknowledged innovator and entrepreneur in the field of biotech. His track records include the foundation of Biosyntech, the first biotech company in Germany, the co-foundation of Milligen/Biosearch and the foundation of Sequenom Inc. As CEO and President of Sequenom he was responsible for one of the most successful US biotech IPOs at the NASDAQ.

After closing a financing round of EUR 6 million, caprotec bioanalytics started operations in January 2008 in Berlin-Adlershof. The Company is supported by an international scientific advisory board including one Nobel Laureate.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements.

For further information please contact:

caprotec bioanalytics GmbH
Corporate Communications
Volmer Str. 5, 12489 Berlin
Tel.: +49 (0)30-6392-3990
Fax: +49 (0)30-6392-3989
info@caprotec.com
www.caprotec.com

